Keyphrases
Multiple Sclerosis
100%
Ocrelizumab
100%
Progressive MS
66%
Disability Worsening
50%
Early Treatment
33%
2-year Follow-up
33%
Clinical Predictors
33%
MRI Activity
33%
Progressive multiple Sclerosis
33%
Immunological Indicators
33%
Adverse Events
16%
Prospective Observational Study
16%
CD8+
16%
Safety Profile
16%
Risk Reduction
16%
Single Center
16%
Safety Data
16%
Therapeutic Effect
16%
Effective Treatment
16%
Treatment Efficacy
16%
Real Patients
16%
Disease Activity
16%
Free Survival
16%
6-month Follow-up
16%
Nave
16%
CD8+ Cells
16%
Previous Treatment
16%
MS Patients
16%
Inflammatory Activity
16%
Severe Adverse Events
16%
Disability Status
16%
Time to First Relapse
16%
Effectiveness Outcomes
16%
Treatment Exposure
16%
Radiological Activity
16%
Relapse Time
16%
NEDA-3
16%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Ocrelizumab
100%
Adverse Event
33%
CD8 Antigen
33%
Observational Study
16%
Disease Activity
16%
Therapeutic Effect
16%
Immunology and Microbiology
Multiple Sclerosis
100%
Ocrelizumab
100%
Magnetic Resonance Imaging
33%
CD8+ Cell
33%
Neuroscience
Multiple Sclerosis
100%
Ocrelizumab
100%
Magnetic Resonance Imaging
33%
CD8
33%